Melinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS
August 03, 2018 13:31 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
July 10, 2018 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the “’Company’) Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Non-Dilutive Funding...
Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
June 11, 2018 07:00 ET
|
Summit Therapeutics plc
Highlights the Power of the Discuva Platform to Identify Novel Antibiotic Targets OXFORD, United Kingdom and CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018
May 31, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance
May 11, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 11, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Accelerate Diagnostics reports Q1 2018 financial results
May 09, 2018 16:03 ET
|
Accelerate Diagnostics, Inc.
TUCSON, Ariz., May 09, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018. The company generated revenue of $801,000, up...
Melinta Therapeutics Reports First Quarter 2018 Financial Results
May 08, 2018 16:01 ET
|
Melinta Therapeutics
Strong Product Sales Performance Across Entire Portfolio Continuing to Optimize Operations to Achieve Cost Synergies Important Achievements for Development and Discovery Efforts Including CARB-X...
Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting
May 08, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria
May 07, 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
April 23, 2018 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic...